Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells.

POLE exonuclease deficiency causes synthetic lethality in highly aneuploid cancer cells, revealing a potential targeted therapy approach.

• Why it matters: Aneuploidy is common in cancer and linked to drug resistance and poor outcomes, yet no treatments specifically target highly aneuploid tumors.
• What they did: Analyzing nearly 500,000 tumor samples and validating with TCGA and CCLE data, the study found mutual exclusivity between POLE exonuclease mutations and high aneuploidy, and used probabilistic modeling to understand this relationship.
• The result: Inhibiting POLE exonuclease activity selectively kills highly aneuploid cancer cells, suggesting a promising strategy for developing targeted therapies against these aggressive tumors.